Netflix earnings are after the bell. Here’s what to expect

Netflix earnings are after the bell. Here’s what to expect


Nurphoto | Nurphoto | Getty Images

LOS ANGELES — Netflix is due to report third-quarter earnings after the closing bell Thursday.

Wall Street will be paying close attention to details surrounding the company’s advertising-supported business model, upcoming live sporting events and the continued effects of its password crackdown on subscriber numbers.

After all, this is one of the last times Netflix will report subscriber data to shareholders, as it plans to focus on revenue and other financial metrics as performance indicators.

Here is what Wall Street expects for the company’s most-recent quarter: 

  • Earnings per share: $5.12, according to LSEG
  • Revenue: $9.76 billion, according to LSEG
  • Paid memberships: 282.15 million, according to StreetAccount

Active subscriber numbers are expected to be flat for the third quarter, as gains from its crackdown on password sharing start to taper off. This has led some Wall Street analysts to predict that Netflix will soon announce price hikes.

New Street Research analyst Dan Salmon and Morgan Stanley analyst Benjamin Swinburne both noted expected price increase announcements in recent research notes to investors.

As of Wednesday’s close, the company’s stock was up 44% year to date and around 95% over the past 12 months.

This is a breaking news story. Please check back for updates.

Don’t miss these insights from CNBC PRO



Source

Nike cuts 1,400 roles in second round of layoffs this year
Business

Nike cuts 1,400 roles in second round of layoffs this year

People walk past a Nike store in New York City, on April 2, 2025. Kylie Cooper | Reuters Nike announced a new round of layoffs on Thursday impacting approximately 1,400 roles across the organization, mostly concentrated in its technology department. In a note from COO Venkatesh Alagirisamy, the company said the layoffs were part of […]

Read More
Trump administration moves to reclassify cannabis in major shift that could expand research
Business

Trump administration moves to reclassify cannabis in major shift that could expand research

The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug’s medical uses. The change would not legalize the drug at the federal level, but shift cannabis from its current status as a Schedule I substance to Schedule III under the U.S. Drug Enforcement Administration’s controlled […]

Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Business

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]

Read More